STADA Arzneimittel — H1 2018 Earnings Presentation
10 slides from STADA Arzneimittel's earnings presentation, Aug 9, 2018
Slide 1: Corporate Presentation H1/2018 Results
CORPORATE PRESENTATION H1/2018 Results August 9, 2018
Slide 2: Disclaimer and Notes
DISCLAIMER AND NOTES This STADA Arzneimittel AG (hereinafter "STADA") presentation is intended for information only. It is not intended as or provided in connection with an offer or solicitation for the purchase or sale of any security in any jurisdiction. STADA shall not have any liability arising
Slide 3: H1/2018 at a Glance
H1/2018 AT A GLANCE Increase of adjusted Group sales driven by both segments Strong increase in both reported and adjusted EBITDA – considerable margin improvement in Generics Significant growth in both reported and adjusted net income STADA’s transformation Agreement with Sanofi on the early
Slide 4: Financial Overview: Business Development as Expected
FINANCIAL OVERVIEW BUSINESS DEVELOPMENT AS EXPECTED Group Results €m H1/20181 H1/2017 Δ Sales 1,137.5 1,143.2 -1% Sales (adj.)2 1,171.6 1,114.5 +5% EBITDA 260.6 220.9 +18% EBITDA (adj.)3 261.7 237.7 +10% Net income 165.3 90.3 +83% Net income (adj.)3 149.7 114.1 +31% 1) STADA Vietnam J.V. Co. Ltd. is
Slide 5: Segment Results – Generics
SEGMENT RESULTS – GENERICS CONSIDERABLE IMPROVEMENT IN PROFITABILITY Sales Sales (adj.)1 EBITDA & Margin (adj.)2 €m €m €m 0% +4% +22% / +500bps 674.4 672.4 660.6 684.7 183.6 150.7 27.3% 22.3% H1/17 H1/18 H1/17 H1/18 H1/17 H1/18 STADA Vietnam J.V. Co. Ltd. is no longer included. 1) Adjusted for curre
Slide 6: Segment Results – Branded Products
SEGMENT RESULTS – BRANDED PRODUCTS GOOD GROWTH IN ADJUSTED SALES Sales Sales (adj.)1 EBITDA & Margin (adj.)2 €m €m €m -1% +7% -1% / -10bps 468.8 465.1 453.9 486.9 121.4 120.0 25.9% 25.8% H1/17 H1/18 H1/17 H1/18 H1/17 H1/18 STADA Vietnam J.V. Co. Ltd. is no longer included. 1) Adjusted for currency a
Slide 7: Positive Cash Flow Development
POSITIVE CASH FLOW DEVELOPMENT €m1 H1/2018 H1/2017 Δ Operating cash flow 95.0 89.5 +6% R&D/Intangibles -181.4 -41.7 >100% Capex/Other -16.2 -26.5 -39% Acquisitions/Disinvestments 3.0 -4.4 >100% Free cash flow (before dividends) -99.6 16.9 >100% Net working capital at €719m (December 31, 2017: €679
Slide 8: Appendix
APPENDIX STADA Corporate Presentation • August 9, 2018 Page 8
Slide 9: Reconciliation H1/2018
RECONCILIATION H1/2018 in €m1 H1/2018 Impairments/ Effects of purchase Severance Change of tax H1/2018 reported write-ups of price allocations payments status of STADA adjusted non-current assets and product Arzneimittel AG acquisitions2 EBITDA 260.6 - -0.3 1.4 - 261.7 Balance from depreciation/amor
Slide 10: Financial Calendar & Contacts
FINANCIAL CALENDAR & CONTACTS Financial Calendar Contact Journalists Frank Staud March 7, 2019 Corporate Communications Publication FY/2018 results Phone: +49 (0) 6101 603-165 May 29, 2019 E-mail: frank.staud@stada.de Annual General Meeting 2019 August 15, 2019 Publication H1/2019 results Cont